A cen­tu­ry af­ter the last ma­jor TB vac­cine break­through, Gates and Well­come com­mit $550M for PhI­II test of GSK shot

Two non­prof­it or­ga­ni­za­tions are team­ing up for a gi­ant study of an ex­per­i­men­tal vac­cine de­signed to pro­tect against the world’s dead­liest in­fec­tious dis­ease.

The Bill and Melin­da Gates Foun­da­tion and Well­come are com­mit­ting $550 mil­lion to fund a Phase III clin­i­cal tri­al of an ex­per­i­men­tal tu­ber­cu­lo­sis vac­cine de­vel­oped by GSK. If the shot proves suc­cess­ful, it could be the first new vac­cine for pre­vent­ing the dead­ly bac­te­r­i­al lung in­fec­tion in more than 100 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER